AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29913339
Drug: Remifentanil (≥0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (≥0.15 µg/kg/min)
Trial: 29914560
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy with CT scans
Trial: 29914560
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of history of severe hemorrhage, dual antiplatelet therapy, headache or vomiting, and abnormal Glasgow coma scale score
Trial: 29914796
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery of a radioimmunotherapy agent targeting B7-H3 antigen, single infusion of 9.25 to 148 MBq at a concentration of about 37 MBq/mL.
Trial: 29914948
Drug: Amoxicillin treatment
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin treatment
Trial: 29917147
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) delivered house-to-house or at a central point, with or without compensation
Trial: 29920582
Drug: Golimumab (GOL)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GOL) 200 mg at week 0, 100 mg at week 2, then 50 mg (<80 kg) or 100 mg (≥80 kg) every 4 weeks thereafter.
Trial: 29921512
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg per day for 4 weeks in repeated 6-week cycles until disease progression or prohibitive toxicity
Trial: 29921622
Drug: Ambulatory patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory patch ECG recorder (Zio XT monitor) fitted in the ED, continuously records a single-lead ECG for up to 14 days.
Trial: 29921622
Drug: Ambulatory patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory patch ECG recorder (Zio XT monitor).
Trial: 29921685
Drug: Combined optimisation
RxNorm normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined optimisation of general anaesthesia involving goal-directed haemodynamic therapy (GDHT), lung-protective ventilation (LPV), and electroencephalographic depth of anaesthesia monitoring (DAM)
Trial: 29922050
Drug: Concurrent asthma
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent asthma diagnosis
Trial: 29923063
Drug: Prophylactic scalp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic scalp cooling (PSC) with ELASTO-GEL hypothermia caps during adjuvant docetaxel treatment
Trial: 29923063
Drug: Adjuvant docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant docetaxel (cumulative dose ≥ 400 mg/m²)
Trial: 29923063
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only endocrine therapy
Trial: 29923931
Drug: Hypertonic lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic lactate (sodium lactate, 1,000 mmol/L; concentration, 30 µmol/kg/min) administered via three-hour IV infusion 39 hours from injury.
Trial: 29924320
Drug: Soluble transferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble transferrin receptor
Trial: 29925497
Drug: CCAT (computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCAT (computerized cognitive addiction therapy) for 4 weeks plus regular detoxification treatment
Trial: 29925497
Drug: Regular detoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular detoxification treatment as usual
Trial: 29925549
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist (DA) use
Trial: 29925549
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist (DA) discontinuation
Trial: 29926288
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of plasma noradrenaline levels with norepinephrine dose
Trial: 29926400
Drug: Ipragliflozin 50
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 50 mg/day for 20 weeks, then 50 or 100 mg/day for 32 weeks
Trial: 29926400
Drug: Ipragliflozin 100
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin 100 mg/day (for patients with insufficient control on 50 mg)
Trial: 29926400
Drug: Ipragliflozin and
RxNorm normalized name: bexagliflozin
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin and GLP-1 receptor agonists/sulfonylureas
Trial: 29926826
Drug: Control (extraventricular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (extraventricular drainage plus urokinase thrombolytic therapy)
Trial: 29927704
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg plague vaccine
Trial: 29927704
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg plague vaccine
Trial: 29927782
Drug: Early-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early-treatment group (15 months or less from diagnosis to cryoablation)
Trial: 29927782
Drug: Late-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late-treatment group (greater than 15 months from diagnosis to cryoablation)
Trial: 29927832
Drug: Mastectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastectomy with temporizing implant, postmastectomy radiotherapy, and DIEP flap reconstruction
Trial: 29927832
Drug: Immediate DIEP
RxNorm normalized name: limonene diepoxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate DIEP flap reconstruction or mastectomy with temporizing implant then DIEP flap surgery
Trial: 29929092
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin (60 mg/m²) and ifosfamide for six cycles
Trial: 29929092
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin and ifosfamide
Trial: 29930021
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg (T90)
Trial: 29930021
Drug: Ticagrelor 60
RxNorm normalized name: ticagrelor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 60 mg (T60)
Trial: 29931068
Drug: 25-Hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-Hydroxyvitamin D deficiency (<20 ng/mL)
Trial: 29931068
Drug: 25-Hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-Hydroxyvitamin D replete (≥30 ng/mL)
Trial: 29932498
Drug: Structured light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured light plethysmography (SLP) before bronchodilator treatment
Trial: 29932498
Drug: Structured light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured light plethysmography (SLP) after bronchodilator treatment
Trial: 29933073
Drug: CC-486 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (200 mg, n=3; 300 mg, n=4) once daily for 7 days per cycle
Trial: 29933073
Drug: CC-486 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (150 mg, n=4; 200 mg, n=19) for 14 days per cycle
Trial: 29933073
Drug: CC-486 maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CC-486 maintenance therapy
Trial: 29933095
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg orally, twice daily) combined with gemcitabine (1000 mg/m2) and cisplatin chemotherapy
Trial: 29933272
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion at target plasma concentrations of 0.3, 0.6, 1.2, and 2.4 ng/mL
Trial: 29934393
Drug: Concurrent HP-HD
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent HP-HD
Trial: 29934393
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (HP, HD, concurrent HP-HD, Control)
Trial: 29934438
Drug: LTA agonist
RxNorm normalized name: lidocaine hydrochloride Mucous Membrane Topical Solution [LTA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTA agonist and native LGG
Trial: 29934438
Drug: CXCR4 agonist
RxNorm normalized name: CXCR4 INHIBITOR X4P-001
DrugBank: Mavorixafor (DB05501)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXCR4 agonist
Trial: 29934842
Drug: Permanent Iodine-125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Permanent Iodine-125 Seed Implantation, median biologically effective dose (BED) about 180 Gy
Trial: 29935143
Drug: Early capsule
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early capsule endoscopy
Trial: 29936063
Drug: IMAB362 (Zolbetuximab)
RxNorm normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMAB362 (Zolbetuximab) 33, 100, 300, 600, and 1000 mg/m2 single dose
Trial: 29936063
Drug: IMAB362 (Zolbetuximab)
RxNorm normalized name: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMAB362 (Zolbetuximab) 600 mg/m2 single dose
Trial: 29936064
Drug: nab-paclitaxel 120
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 120 mg/m²
Trial: 29936064
Drug: nab-paclitaxel 240
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 240 mg/m²
Trial: 29936086
Drug: Prior diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior diabetes treatment assignment
Trial: 29936438
Drug: TNFi monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFi monotherapy
Trial: 29938772
Drug: Twice-weekly ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly ixazomib 3·0 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone.
Trial: 29938772
Drug: Twice-weekly ixazomib-Rd
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly ixazomib-Rd
Trial: 29938825
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood insulin
Trial: 29940782
Drug: Stimulant medication
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant medication (single dose)
Trial: 29942666
Drug: FOLFOX (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX (standard therapy)
Trial: 29944518
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IVI) treatment with ferric carboxymaltose (500-1000 mg)
Trial: 29944518
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous iron (IVI) treatment
Trial: 29944518
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IVI) treatment
Trial: 29944518
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (IVI) treatment and no IVI treatment
Trial: 29945665
Drug: Formulations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations of magnesium sulphate
Trial: 29945738
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg/day) / Levocetirizine (5 mg/day)
Trial: 29946005
Drug: Nintedanib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib added to pirfenidone treatment
Trial: 29946005
Drug: Pirfenidone (1602-2403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirfenidone (1602-2403 mg·day)
Trial: 29946013
Drug: Hemoglobin concentration
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin concentration >10 g/dL
Trial: 29947745
Drug: Drug abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug abuse in the family
Trial: 29947806
Drug: Maternal serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal serum cobalamin concentration <394 pmol/L at week 18
Trial: 29948356
Drug: Sonidegib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib plus docetaxel (fixed dose at 75 mg/m2)
Trial: 29948566
Drug: Once-daily PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily PPI therapy
Trial: 29948566
Drug: Twice-daily PPI
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily PPI therapy
Trial: 29948566
Drug: Aspirin/NSAID use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin/NSAID use
Trial: 29949102
Drug: Verinurad 15
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 15 mg administered orally under fasted conditions
Trial: 29950123
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany)
Trial: 29950463
Drug: ACL reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACL reconstruction (for participants who have surgical treatment)
Trial: 29950465
Drug: Real-time audio-visual
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time audio-visual feedback on TSD to caregivers via premounted handhelds and tablets
Trial: 29950475
Drug: Exenatide (add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (add-on treatment to insulin therapy)
Trial: 29951694
Drug: Belinostat (48-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belinostat (48-h continuous intravenous infusion)
Trial: 29951694
Drug: Higher belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher belinostat drug exposure
Trial: 29951694
Drug: q3week schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q3week schedule of belinostat infusion
Trial: 29951750
Drug: Multifaceted individualized
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted individualized pneumoperitoneum strategy (ventilation with low tidal volume, modified lithotomy position, deep neuromuscular blockade, pre-stretching of the abdominal wall, individualized intra-abdominal pressure titration)
Trial: 29951977
Drug: Pregabalin (stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (stepwise dose escalation from 75 mg to 600 mg daily)
Trial: 29952895
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment (n = 6)
Trial: 29953745
Drug: Muscle co-activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle co-activation strategies during activities of daily living
Trial: 29954415
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and rituximab maintenance therapy
Trial: 29954418
Drug: search and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment
Trial: 29954418
Drug: continuous suppression
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment
Trial: 29954932
Drug: Ixazomib-melphalan-prednisone regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib-melphalan-prednisone regimen (ixazomib 4.0 mg [days 1, 8, 15] plus melphalan-prednisone 60 mg/m)
Trial: 29954932
Drug: Single-agent ixazomib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent ixazomib maintenance
Trial: 29955707
Drug: Combined Carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Carbohydrate and Essential Amino Acid Supplement
Trial: 29955710
Drug: Daily Ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Ethanol Consumption
Trial: 29955789
Drug: P4 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P4 levels 60-100 nmol/l in early luteal phase
Trial: 29955789
Drug: P4 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P4 levels >400 nmol/l in early luteal phase
Trial: 29955789
Drug: P4 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P4 levels 150-250 nmol/l in mid-luteal phase
Trial: 29955789
Drug: P4 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P4 levels >400 nmol/l in mid-luteal phase
Trial: 29955792
Drug: Tucatinib 300
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib 300 mg administered orally twice per day for 21 days and T-DM1 3.6 mg/kg administered intravenously once every 21 days.
Trial: 29959809
Drug: Ceritinib (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceritinib (750 mg/day fasted)
Trial: 29960116
Drug: Low-zinc group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-zinc group (zinc level <71 μg/dl)
Trial: 29960116
Drug: Normal-zinc group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-zinc group (zinc level ≥71 μg/dl)
Trial: 29960692
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and CBT
Trial: 29960692
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment response
Trial: 29961023
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training (IMT) using a tapered flow resistive loading device (POWERbreathe KH2, HaB International, UK), four sets of 6-10 breaths daily against an external load, adjusted to the highest tolerable load.
Trial: 29961037
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 50 Allergan Units of botulinum toxin A (BTA) resuspended in 1 mL saline + splinting
Trial: 29961037
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection (1 mL) + splinting
Trial: 29961037
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of 50 Allergan Units of BTA + splinting
Trial: 29961213
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide (HP) gel (control)
Trial: 29961246
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 0.3 U/kg (high dose corticosteroids group)
Trial: 29961246
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin 0.15 U/kg (low dose corticosteroids group)
Trial: 29961557
Drug: Cost drivers
RxNorm normalized name: river birch pollen extract
DrugBank: Betula nigra pollen (DB10458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost drivers associated with therapies received
Trial: 29961557
Drug: Monthly direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly direct costs per patient during distant metastasis/terminal illness phase
Trial: 29961557
Drug: Monthly direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly direct costs per patient during adjuvant treatment period
Trial: 29962529
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of IV parecoxib
Trial: 29962926
Drug: Carvedilol 12.5
RxNorm normalized name: carvedilol 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5 mg single oral dose for 3 days, then 25 mg QD for 5 days, and 12.5 mg QD for another 3 days